
|Articles|May 1, 2003
Gatifloxacin approved
Author(s)Scott M. Whitcup, MD, Ed Edelson
CA-The FDA approval of gatifloxacin ophthalmic solution 0.3% (Zymar, Allergan) marks a milestone as the first fourth-generation fluoroquinolone to enter the ophthalmic market. The therapy for the treatment of bacterial conjunctivitis caused by susceptible strains of bacteria also has a unique mechanism to prevent development of antibiotic resistance, according to Allergan.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
REGENXBIO completes enrollment in ATMOSPHERE and ASCENT trials of sura-vec in wet AMD
2
Academy technician training platform expands education opportunities in ophthalmology
3
Increasing the knowledge base of GA is key to individualizing patient therapy
4
Ocular surface: Targeted therapies for a multifactorial problem
5